Basal cell carcinomas (BCCs) are locally destructive malignancies of
the skin. They are the most common type of cancer in the western
world. The lifetime incidence may be up to 39%. UV exposure is the
most common risk factor. The majority of these tumours occur on the
head and neck. Despite BCCs being relatively indolent the high
incidence means that their treatment now contributes a significant and
increasing workload for the health service. A good understanding of
the options available is important. Management decisions may be
influenced by various factors including the patient's age and
comorbidities and the lesion subtype and location. Due to the
importance of a good cosmetic and curative outcome for facial BCCs
treatment decisions may differ significantly to those that would be
made for BCCs arising elsewhere. There is little good randomized
controlled data available comparing treatment modalities. Although
traditionally standard excision has been the treatment of choice
various other options are available including: Mohs micrographic
surgery, curettage and cautery, cryosurgery, radiotherapy, topical
imiquimod, photodynamic therapy and topical 5-fluorouracil. We
discuss and review the literature and evidence base for the treatment
options that are currently available for facial BCCs.